Monoclonal antibody therapeutics: The need for biopharmaceutical reference materials

ACS Symposium Series

Volumn 1176, Issue , 2014, Pages 1-34

  Schiel, John E ^a   Mire Sluis, Anthony ^b   Davis, Darryl ^c  

^a NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

^b AMGEN INC   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL CULTURE; CELL CULTURE; DISEASE CONTROL; DRUG PRODUCTS; LIFE CYCLE; MAMMALS; MONOCLONAL ANTIBODIES;

ANTIBODY THERAPEUTICS; FOLLOW-ON BIOLOGICS; MAMMALIAN CELL CULTURE; PERFORMANCE SPECIFICATIONS; PRODUCT INFORMATION; REFERENCE STANDARD; THERAPEUTIC MONOCLONAL ANTIBODIES; WEALTH OF INFORMATION;

ANTIBODIES;

EID: 84927135893     PISSN: 00976156     EISSN: 19475918     Source Type: Book Series    
DOI: 10.1021/bk-2014-1176.ch001     Document Type: Article

References (99)

1. Wachtel-Galor, S; Benzi, I. Herbal Medicine: Biomolecular and Clinical Aspects; CRC Press: Boca Raton, FL, 2011.
2. Jones, A. W. Early drug discovery and the rise of pharmaceutical chemistry. Drug Test. Anal. 2011, 3, 337-44.
3. Kumar, H.; Kawai, T.; Akira, S. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 2011, 30, 16-34.
4. Goldsby, R.; Kindt, T.; Osborne, B.; Kuby, J. Immunology, 5th ed.; W.H. Freeman and Company: New York, 2003.
5. Deng, L.; Luo, M; Velikovsky, A.; Mariuzza, R. Structural insights into the evolution of the adaptive immune system. Annu. Rev. Biophys. 2013, 42, 191-215.
6. Parra, D.; Takizawa, F.; Sunyer, J. O. Evolution of B cell immunity. Annu. Rev. Anim. Biosci. 2013, 1, 65-97.
7. Von Behring, E.; Kitastato, S. Über das zustandekommen der diphtherie-immunitat und dr tetanus-immunitat bei tieren. Dtsch. Med. Wochenschr 1890, 16, 1113-1114.
8. Cenci, F. Alcune experienze di sieroimmunizzaziuone e sieroterapie nel norbillo. Riv. Clin. Pediatr. 1907, 5, 1017-1025.
9. Cohn, E. Blood proteins and their therapeutic value. Science 1945, 101, 51-56.
10. Cohn, E. J.; Strong, L. E.; Hughes, W. L.; Mulford, D. J.; Ashworth, J. N.; Melin, M. Preparation and Properties of Serum. J. Am. Chem. Soc. 1946, 68, 459-475.
11. Eibl, M. M. History of immunoglobulin replacement. Immunol. Allergy Clin. North Am. 2008, 28, 737-64, viii.
12. Kohner, G.; Millstein, C. Continuous cultures of fused cells secrieting antibody of predefined specificity. Nature 1975, 256, 495-497.
13. General Policies for Monoclonal Antibodies; INN Working Document 09.251; World Health Organization: Geneva, Switzerland, 2009.
14. International Nonproprietary Names (INN) for Biological and Biotechnological Substances (A Review); INN Working Document 05.179; World Health Organization: Geneva, Switzerland, 2013.
15. Van den Hoogen, M. W F.; Hilbrands, L. B. Use of monoclonal antibodies in renal transplantation. Immunotherapy 2011, 3, 871-80.
16. Smith, S. L. Ten years of Orthoclone OKT3. J. Transpl. Coord. 1996, 6, 109-121.
17. Jones, S. D.; Castillo, F. J.; Levine, H. L. Advances in the development of therapeutic monoclonal antibodies. BioPharm Int. 2007 96-114.
18. Delmonico, F.; Fuller, T.; Russell, P. Variation in patient response associated with different preparations of murine monoclonal antibody therapy. Transplantation 1989, 47, 92-95.
19. Caron, P. C; Schwartz, M. a; Co, M. S.; Queen, C; Finn, R. D.; Graham, M. C; Divgi, C. R.; Larson, S. M; Scheinberg, D. a. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) forthe therapy of acute myelogenous leukemia. Cancer 1994, 73, 1049-56.
20. Li, F.; Vijayasankaran, N; Shen, A. (Yijuan); Kiss, R.; Amanullah, A. Cell culture processes for monoclonal antibody production. mAbs 2010, 2, 466-179.
21. Neslon, D.; Cox, M. Principles of Biochemistry, 4th ed.; W.H. Freeman and Company: New York, 2005; pp 307-317.
22. Cacciatore, J. J.; Chasin, L. a; Leonard, E. F. Gene amplification and vector engineering to achieve rapid and high-level therapeutic protein production using the Dhfr-based CHO cell selection system. Biotechnol. Adv. 2010, 28, 673-81.
23. Bandaranayake, A. D.; Almo, S. C. Recent advances in mammalian protein production. FEES Lett. 2014, 588, 253-60.
24. Morrison, S. L.; Johnson, M. J.; Herzenberg, L. a; Oi, V. T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 6851-6855.
25. Knight, D. M; Trinh, H.; Le, J.; Siegel, S.; Shealy, D.; McDonough, M; Scallon, B.; Moore, M. A.; Vilcek, J.; Daddona, P. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 1993, 30, 1443-1453.
26. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl. J. Med. 1994, 330, 956-961.
27. Knight, D. M.; Wagner, C; Jordan, R.; McAleer, M. F.; DeRita, R.; Fass, D. N.; Coller, B. S.; Weisman, H. F.; Ghrayeb, J. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol. Immunol. 1995, 32, 1271-1281.
28. Jones, P.; Dear, P.; Foote, J.; Neuberger, M.; Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321, 522-525.
29. Coco-Martin, J.; Harmsen, M. A review of therapeutic protein expression by mammalian cells. Bioprocess Int. 2008, 28-33.
30. Birch, J. R.; Racher, A. J. Antibody production. Adv. Drug Delivery Rev. 2006, 58, 671-685.
31. Bosques, C; Collins, B.; Meador, J.; Sarvaiya, H.; Murphy, J.; DelloRusso, G.; Bulik, D.; Hus, I.; Washburn, N.; Sipset, S.; Myette, J.; Raman, R. Chinese hamster ovary cells can produce galactose-a-1,3-galactose. Nature 2010, 28, 1153-1156.
32. Lonberg, N.; Taylor, L.; Harding, F. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994, 368, 856-859.
33. McCafferty, J.; Griffiths, A.; Winter, G.; Chiswell, D. Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 1990, 348, 522-554.
34. Nelson, A. L.; Dhimolea, E.; Reichert, J. M. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discovery 2010, 9, 767-74.
35. Mease, P. J. Adalimumab in the treatment of arthritis. Then Clin. Risk Manage. 2007, 3, 133-148.
36. Yallop, C; Crowley, J. PER.C6® Cells for the Manufacture of Biopharmaceutical Proteins. In Modern Biopharmaceuticals: Design, Development and Optimization; Knablein, J., Ed.; Wiley: Weinheim, 2008; pp 779-808.
37. Zhu, J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol. Adv. 2012, 30, 1158-70.
38. Spadiut, O.; Capone, S.; Krainer, F.; Glieder, A.; Herwig, C. Microbials for the production of monoclonal antibodies and antibody fragments. Trends Biotechnol. 2014, 32, 54-60.
39. Ghaderi, D.; Zhang, M.; Hurtado-Ziola, N.; Varki, A. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol. Genet. Eng. Rev. 2012, 28, 147-176.
40. Spada, S.; Walsh, G. Directory of Approved Biopharmaceuticals; CRC Press: Boca Raton, FL, 2004.
41. E-mail: Drugs@FDA.com.
42. Rajpal, A.; Strop, P.; Yeung, Y; Chaparro, J.; Pons, J. Introduction: Antibody structure and function. In Therapeutic Fc-Fusion Proteins; Wiley, New York, 2014; pp 1-28.
43. Nelson, A. L. Antibody fragments: Hope and hype. mAbs 2010, 2, 77-83.
44. Wu, B.; Sun, Y.-N. Pharmacokinetics of Peptide-Fc fusion proteins. J. Pharm. Sci. 2014, 103, 53-64.
45. Shapiro, A. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia. Expert Opin. Biol. Then 2013, 13, 1287-97.
46. Kaufman, R.; Powell, J. Molecular approaches for improved clotting factors for hemophilia. Blood 2013, 122, 3568-3574.
47. Sliwkowski, M. X.; Mellman, I. Antibody therapeutics in cancer. Science 2013, 341, 1192-8.
48. Byrne, H.; Conroy, P. J.; Whisstock, J. C; O'Kennedy, R. J. A tale of two specificities: Bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol. 2013, 37, 621-32.
49. Frankel, S. R.; Baeuerle, P. A. Targeting T cells to tumor cells using bispecific antibodies. Curr. Opin. Chem. Biol. 2013, 17, 385-392.
50. Ahmad, Z. A.; Yeap, S. K.; Ali, A. M.; Ho, W Y; Alitheen, N. B. M.; Hamid, M. scFv antibody: Principles and clinical application. Clin. Dev. Immunol. 2012, 2012, 1-15.
51. Hess, C; Venetz, D.; Neri, D. Emerging classes of armed antibody therapeutics against cancer. MedChemComm 2014, 5, 408-431.
52. ICH Topic Q 6 B. Specifications, Test Procedures and Acceptance Criteria for Biotechnological Products. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 1999.
53. Marichal-Gallardo, P. A; Alvarez, M. M. State-of-the-art in downstream processing of monoclonal antibodies: Process trends in design and validation. Biotechnol. Prog. 2012, 28, 899-916.
54. Shukla, A. a; Thömmes, J. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 2010, 28, 253-61.
55. Butler, M; Meneses-Acosta, a. Recent advances in technology supporting biopharmaceutical production from mammalian cells. Appl. Microbiol. Biotechnol. 2012, 96, 885-94.
56. Hou, J. J. C; Codamo, J.; Pilbrough, W.; Hughes, B.; Gray, P. P.; Munro, T. P. New frontiers in cell line development: challenges for biosimilars. J. Chem. Technol. Biotechnol. 2011, 86, 895-904.
57. Shukla, A. a; Gottschalk, U. Single-use disposable technologies for biopharmaceutical manufacturing. Trends Biotechnol. 2013, 37, 147-54.
58. Read, E. K.; Park, J. T.; Shah, R. B.; Riley, B. S.; Brorson, K. a; Rathore, a S. Process analytical technology (PAT) for biopharmaceutical products: Part I. Concepts and applications. Biotechnol. Bioeng. 2010, 105, 276-84.
59. Kelley, B.; Blank, G.; Lee, A. Downstream Processing of Monoclonal Antibodies: Current Practices and Future Opportunities. In Process Scale Purification of Antibodies; Gottschalk, U., Ed.; Wiley: Hoboken, NJ, 2009; pp 1-24.
60. Shukla, A. A.; Hubbard, B.; Tressel, T.; Guhan, S.; Low, D. Downstream processing of monoclonal antibodies: Application of platform approaches. J. Chromatogr. B 2007, 848, 28-39.
61. Fahrner, R.; Knudsen, H.; Basey, C; Galan, W.; Feuerhelm, D.; Vanderlaan, M; Blank, G. Industrial purification of pharmaceutical antibodies: Development, operation, and validation of chromatography processes. Biotechnol. Genet. Eng. Rev. 2001, 18, 301-327.
62. Ghose, S.; Hubbard, B.; Cramer, S. M. Binding capacity differences for antibodies and Fc-fusion proteins on protein A chromatographic materials. Biotechnol. Bioeng. 2007, 96, 768-779.
63. Tugcu, N.; Roush, D. J.; Goklen, K. E. Maximizing productivity of chromatography steps for purification of monoclonal antibodies. Biotechnol. Bioeng. 2008, 99, 599-613.
64. Ghose, S.; Al, E. USe and optimization of dual flow-rate loading strategy for maximizing throughput in protein A affinity chromatgrpahy. Biotechnol. Prog. 2004, 20, 830-840.
65. Jiang, C; Liu, J.; Rubacha, M.; Shukla, A. A. A mechanistic study of Protein A chromatography resin lifetime. J. Chromatogr. A 2009, 1216, 5849-5855.
66. Shukla, A. A.; Hinckley, P. Host cell protein clearance during Protein A chromatography: Development of an improved column wash step. Biotechnol. Prog. 2008, 24, 1115-1121.
67. Levy, N. E.; Valente, K. N.; Choe, L. H.; Lee, K. H.; Lenhoff, A. M. Identification and characterization of host cell protein product-associated impurities in monoclonal antibody bioprocessing. Biotechnol. Bioeng. 2013, 9999, 1-9.
68. Ghose, S.; Jin, M.; Liu, J.; Hickey, J. Integrated Polishing Steps for Monoclonal Antibody Purification. In Process Scale Purification of Antibodies; Gottschalk, U., Ed.; John Wiley and Sons: Hoboken, NJ, 2009; pp 145-168.
69. Tscheliessnig, A. L.; Konrath, J.; Bates, R.; Jungbauer, A. Host cell protein analysis in therapeutic protein bioprocessing: Methods and applications. Biotechnol. J. 2013, 8, 655-70.
70. Barroso, T.; Hussain, A.; Roque, A. C. a; Aguiar-Ricardo, A. Functional monolithic platforms: Chromatographic tools for antibody purification. Biotechnol. J. 2013, 8, 671-81.
71. Kallberg, K.; Johansson, H.-O.; Bulow, L. Multimodal chromatography: An efficient tool in downstream processing of proteins. Biotechnol. J. 2012, 7, 1485-95.
72. Wang, X.; Hunter, A. K.; Mozier, N. M. Host cell proteins in biologics development: Identification, quantitation and risk assessment. Biotechnol. Bioeng. 2009, 103, 446-58.
73. Schenauer, M. R.; Flynn, G. C; Goetze, A. M. Identification and quantification of host cell protein impurities in biotherapeutics using mass spectrometry. Anal. Biochem. 2012, 428, 150-7.
74. Valente, K. N.; Schaefer, A. K.; Kempten, H. R.; Lenhoff, A. M.; Lee, K. H. Recovery of Chinese hamster ovary host cell proteins for proteomic analysis. Biotechnol. J. 2014, 9, 87-99.
75. Jeong, S. H. Analytical methods and formulation factors to enhance protein stability in solution. Arch. Pharm. Res. 2012, 35, 1871-86.
76. Q8(R2). Pharmaceutical Development. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 2009.
77. A-Mab: A Case Study in Bioprocess Development, version 2.1; CMC Biotech Working Group, 2009.
78. Justice, C; Brix, A.; Freimark, D.; Kraume, M.; Pfromm, P.; Eichenmueller, B.; Czermak, P. Process control in cell culture technology using dielectric spectroscopy. Biotechnol. Adv. 2011, 29, 391-401.
79. Rathore, a S.; Bhambure, R.; Ghare, V Process analytical technology (PAT) for biopharmaceutical products. Anal. Bioanal. Chem. 2010, 398, 137-54.
80. Streefland, M.; Martens, D. E.; Beuvery, E. C; Wijffels, R. H. Process analytical technology (PAT) tools for the cultivation step in biopharmaceutical production. Eng. Life Sci. 2013, 73, 212-223.
81. Awotwe-Otoo, D.; Agarabi, C.; Khan, M. a. An integrated process analytical technology (PAT) approach to monitoring the effect of supercooling on lyophilization product and process parameters of model monoclonal antibody formulations. J. Pharm. Sci. 2014, 103, 2042-52.
82. Mercier, S. M.; Diepenbroek, B.; Wijffels, R. H.; Streefland, M. Multivariate PAT solutions for biopharmaceutical cultivation: urrent progress and limitations. Trends Biotechnol. 2014, 32, 329-336.
83. Read, E. K.; Shah, R. B.; Riley, B. S.; Park, J. T.; Brorson, K. a; Rathore, a S. Process analytical technology (PAT) for biopharmaceutical products: Part II. Concepts and applications. Biotechnol. Bioeng. 2010, 105, 285-95.
84. Federici, M.; Lubiniecki, A.; Manikwar, P.; Volkin, D. B. Analytical lessons learned from selected therapeutic protein drug comparability studies. Biologicals 2013, 41, 131-47.
85. Douette, P.; Bolon, P. Analytical Method Lifecycle: A Roadmap for Biopharmaceutical development. Biopharm Int. 2013, 46-53.
86. Q2(R1) Validation of Analytical Procedures. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 2005.
87. Blood Products and Related Biologicals. World Health Organization, http://www.who.int/bloodproducts/ref-materials/en/ (accessed March 7, 2014).
88. Williams, R. L. Official USP Reference Standards: Metrology concepts, overview, and scientific issues and opportunities. J. Pharm. Biomed. Anal. 2006, 40, 3-15.
89. Bhattacharyya, L.; Cecil, T.; Dabbah, R.; Roll, D.; Schuber, S.; Sheinin, E. B.; Williams, R. L. The value of USP public standards for therapeutic products. Pharm. Res. 2004, 21, 1725-31.
90. USP Guideline for Submitting Requests for Revision to USP-NF. U.S. Pharmacopeia Convention, 2011, vol. 5, pp 1-5; http://www.usp.org/uspnf/development-process/submit-new-monographs/submission-guidelines.
91. Rituximab Final Authorized, version 1.0. U.S. Pharmacopeia Convention. https://mc.usp.org/monographs/rituximab-l-0.
92. USP. <129> Analytical Procedures for Recombinant Therapeutic Monoclonal Antibodes. Pharmacopeal Forum 2013, 39, 2368-2368.
93. Rituximab. Monographs on Biological Products for Incorporation in IP-2014. National Institute of Biologicals. http://nib.gov.in/Monographs-developed.html (accessed March 7, 2014).
94. Draft Guidance for Industry Bioanalytical Method Validation. Federal Register, September 13, 2013.
95. Apostel, L; Krall, L; Kelner, D. Analytical Method Validation for Biopharmaceuticals. In Analytical Chemistry; InTech: Rijeka, Croatia, 2012; pp 115-134.
96. Rozet, E.; Marini, R. D.; Ziemons, E.; Boulanger, B.; Hubert, P. Advances in validation, risk and uncertainty assessment of bioanalytical methods. J. Pharm. Biomed. Anal. 2011, 55, 848-58.
97. Schiel, J. E.; Au, J.; He, H.-J.; Phinney, K. W. LC-MS/MS biopharmaceutical glycoanalysis: Identification of desirable reference material characteristics. Anal. Bioanal. Chem. 2012, 403, 2279-89.
98. Terms and Definitions Used in Connection with Reference Materials. ISO Guide 30:1992/Amd 1:2008; ISO (International Organization for Standardization): Geneva, Switzerland, 2008.
99. Reichert, J. M. Antibodies to watch in 2013: Mid-year update. mAbs 2013, 5, 513-7.